Merck KGaA plans to invest €50 million (68 million USD) in its Italian production site in Bari to respond to the rising demand for biopharmaceuticals, the company announced in a press release. The expansion is part of the company's "Fit for 2018" transformation and growth program. 

 Within the biopharmaceuticals division, the Bari site is part of Merck's fill & finish operations, along with facilities in Darmstadt and Aubonne (Switzerland). The drugs produced within this global network, particularly those used to treat infertility, are experiencing long-term growing demand. The new production facility in Bari will be commissioned in 2017 for the sterile filling and packaging of liquid drugs into syringes, vials, and ampoules. 

Development

Drug Delivery

Formulation

Formulation and Drug Delivery, Liquids

Formulation and Drug Delivery, Parenterals

Manufacturing, Fill/Finish

News

Merck KGaA fill-finish expansion in Italy will be completed in 2017.